Arvinas and Pfizer announce initial Phase 1b Data from the TACTIVE-U sub-study of Vepdegestrant in… EP News Bureau Dec 11, 2024 Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate: 62.5 per cent;…
PROTACs oncology market to hit $3.7 billion by 2030 despite lack of approved therapies: GlobalData EP News Bureau Jun 4, 2024 The PROTAC oncology market is projected to capture $3.7 billion by 2030 Proteolysis targeting chimeras (PROTACs) are a…
